局部晚期食管癌放化疗综合治疗新进展

New progress in locally advanced esophageal cancer comprehensive therapy

食管癌(esophagea cancer)起病隐袭,早期诊断率低,绝大部分失去手术机会。单纯放疗生存率较低,因此放化联合治疗成为治疗食管癌的趋势。但放化疗中放疗剂量、化疗药物选择、放化顺序仍未统一。靶向药物联合放化疗仍处于研究的初期,结果令人期待。另外,免疫治疗、生物化疗等新治疗手段和理念也逐渐成为学者关注及研究热点。

Esophageal carcinoma is a malignancy with a poor prognosis. Most patients with local ly advanced esopha-geal cancer eithernot candidates for surgical treatment or prefer not to undergo surgery. Survival rate of radiation thera-py alone is low, such patients are often treated with chemotherapy and radiation therapy. Nevertheless, the radiation dose,chemotherapy drug,sequence of chemoradiotherapy is still no unified. The understanding of targeteddrugs in che- moradiotherapy is still in early stage,but the result is worth looking forward to. In addition,novel treatments and con-cepts, including immune therapy and biological chemotherapy, are attracting more and more attention.